Pharmacokinetics of different selenium supplements in healthy individuals and patients with autoimmune thyroiditis after oral administration
DOI:
https://doi.org/10.20450/mjcce.2025.3111Keywords:
selenium, selenomethionine, pharmacokinetics, autoimmune thyroiditisAbstract
Selenium is essential for the function of key selenoproteins such as glutathione peroxidase, thiore-doxin reductase, and iodothyronine deiodinase, which have antioxidant properties and support thyroid hormone metabolism. Due to the low selenium content in European soils – particularly in the Southeast-ern regions, supplementation is often recommended, especially for conditions like Hashimoto's thyroidi-tis. However, careful consideration of selenium dosage and pharmacokinetics is crucial, as the margin be-tween essential and toxic levels is very narrow. The aim of this study was to investigate the pharmacoki-netics of selenium absorption and plasma concentration following oral administration of various selenium doses and chemical forms, both in the short and long term, in healthy individuals and patients with auto-immune thyroiditis. Selenium concentrations in blood plasma were measured using electrothermal atomic absorption spectrometry (ETAAS). The study found that L-selenomethionine is absorbed more efficiently than inorganic sodium selenite, with peak plasma concentrations reached and sustained within 6 – 8 hours. Selenium levels remained elevated 48 hours after ingestion compared to baseline. At a daily dose of 200 μg of selenium as L-selenomethionine, plasma selenium concentrations increased by approximate-ly 30 %, and by about 25 % at 100 μg/day, relative to the initial value. Long-term studies showed that plasma selenium concentrations rose significantly after the first month of supplementation, with a slower increase in subsequent months. After supplementation ended, selenium levels declined rapidly. Interest-ingly, no significant differences in selenium absorption or excretion were observed between patients with Hashimoto's thyroiditis and healthy controls.
References
(1) Chung, C. Z.; Krahn, N. The selenocysteine toolbox: A guide to studying the 21st amino acid. Arch. Biochem. Biophys. 2022, 730, 109421. https://doi.org/10.1016/j.abb.2022.109421.
(2) Driscoll, D. M.; Copeland, P. R. Mechanism and regulation of selenoprotein synthesis. Annu. Rev. Nutr. 2003, 23, 17-40. https://doi.org/10.1146/annurev.nutr.23.011702.073318.
(3) Minich, W. B. Selenium metabolism and biosynthesis of selenoproteins in the human body. Biochemistry (Moscow). 2022, 87(Suppl. 1). https://doi.org/10.1134/S0006297922140139.
(4) Chu, F. F.; Doroshow, J. H.; Esworthy, R. S. Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI. J. Biol. Chem. 1993, 268, 2571–2576. https://doi.org/10.1016/S0021-9258(18)53812-6.
(5) Pei, J.; Pan, X.; Wei, G.; Hua, Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front. Pharmacol. 2023, 14, 1147414. https://doi.org/10.3389/fphar.2023.1147414.
(6) Fairweather-Tait, S. J.; Collings, R.; Hurst, R. Selenium bioavailability: current knowledge and future research requirements. Am. J. Clin. Nutr. 2010, 91(5), 1484S-1491S. https://doi.org/10.3945/ajcn.2010.28674J.
(7) Arnér, E. S. Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions. Biochim. Biophys. Acta. 2009, 1790, 495-526. https://doi.org/10.1016/j.bbagen.2009.01.014.
(8) Köhrle, J.; Jakob, F.; Contempré, B.; Dumont, J. E. Selenium, the thyroid, and the endocrine system. Endocr. Rev. 2005, 26, 944-984. https://doi.org/10.1210/er.2001-0034.
(9) Bianco, A. C.; Salvatore, D.; Gereben, B.; Berry, M. J.; Larsen, P. R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 2002, 23, 38-89. https://doi.org/10.1210/edrv.23.1.0455.
(10) Kryukov, G. V.; Castellano, S.; Novoselov, S. V.; Lobanov, A. V.; Zehtab, O.; Guigó, R.; Gladyshev, V. N. Characterization of mammalian selenoproteomes. Science 2003, 300, 1439-1443. https://doi.org/10.1126/science.1083516.
(11) Lamarche, J.; Ronga, L.; Szpunar, J.; Lobinski, R. Characterization and quantification of selenoprotein P: Challenges to mass spectrometry. Int. J. Mol. Sci. 2021, 22, 6283. https://doi.org/10.3390/ijms22126283.
(12) Ferreira, R. L. U.; Sena-Evangelista, K. C. M.; de Azevedo, E. P.; Pinheiro, F. I.; Cobucci, R. N.; Pedrosa, L. F. C. Selenium in human health and gut microflora: Bioavailability of selenocompounds and relationship with diseases. Front. Nutr. 2021, 8, 685317. https://doi.org/10.3389/fnut.2021.685317.
(13) Kieliszek, M. Selenium—Fascinating Microelement, Properties and Sources in Food. Molecules 2019, 24(7), 1298. https://doi.org/10.3390/molecules24071298.
(14) Sherovski, P.; Ristovska, N.; Bogdanov, J.; Stafilov, T. Determination of selenium in selected foods from North Macedonia by ETAAS followed by microwave-assisted digestion. JAFES 2022, 76(2), 36-46. https://doi.org/10.55302/JAFES22762036sh
(15) Rayman, M. P. Selenium intake, status, and health: a complex relationship. Hormones 2020, 19, 9–14. https://doi.org/10.1007/s42000-019-00125-5.
(16) Tinggi, U. Essentiality and toxicity of selenium and its status in Australia: a review. Toxicol. Lett. 2003, 137, 103-110. https://doi.org/10.1016/s0378-4274(02)00384-3.
(17) Zuo, Y.; Li, Y.; Gu, X.; Lei, Z. The correlation between selenium levels and autoimmune thyroid disease: a systematic review and meta-analysis. Ann. Palliat. Med. 2021, 10(4), 4398–4408. https://doi.org/10.21037/apm-21-449.
(18) Gartner, R.; Gasnier, B. C.; Dietrich, J. W.; Krebs, B.; Angstwurm, M. W. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J. Clin. Endocrinol. Metab. 2002, 87(4), 1687–1691. https://doi.org/10.1210/jcem.87.4.8421.
(19) Duntas, L. H.; Mantzou, E.; Koutras, D. A. Effects of a six-month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur. J. Endocrinol. 2003, 148(4), 389–393. https://doi.org/10.1530/eje.0.1480389.
(20) Tian, X.; Li, N.; Su, R.; Dai, C.; Zhang, R. Selenium supplementation may decrease thyroid peroxidase antibody titer via reducing oxidative stress in euthyroid patients with autoimmune thyroiditis. Int. J. Endocrinol. 2020, 2020, 9210572. https://doi.org/10.1155/2020/9210572.
(21) Nacamulli, D.; Mian, C.; Petricca, D.; Lazzarotto, F.; Barollo, S.; Pozza, D.; Masiero, S.; Faggian, D.; Plebani, M.; Girelli, M. E.; Mantero, F.; Betterle, C. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin. Endocrinol. 2010, 73 (4), 535–539. https://doi.org/10.1111/j.1365-2265.2009.03758.x.
(22) Deng, S. Y.; Chen, X. Y.; Wu, L. Y. Influence of selenium on Hashimoto thyroiditis with normal thyroid function. Chin. Gen. Pract. 2013, 16 (70), 2483–2485.
(23) Ventura, M.; Melo, M.; Cartilho, F. Selenium and thyroid disease: From pathophysiology to treatment. Int. J. Endocrinol. 2017, 2017, 1297658. https://doi.org/10.1155/2017/1297658.
(24) European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/QWP/1401/98.
(25) Ashton, K.; Hooper, L.; Harvey, L. J.; Hurst, R. Methods of assessment of selenium status in humans. Am. J. Clin. Nutr. 2009, 89, 2025S−2039S. https://doi.org/10.3945/ajcn.2009.27230F.
(26) Combs, G. F. Biomarkers of selenium status. Nutrients 2015, 7, 2209-2236. https://doi.org/10.3390/nu7042209.
(27) Evans, S. O.; Jacobson, G. M.; Goodman, H. J. B.; Bird, S.; Jameson, M. B. Comparative safety and pharmacokinetic evaluation of three oral selenium compounds in cancer patients. Biol. Trace Elem. Res. 2019, 189 (2), 395-404. https://doi.org/10.1007/s12011-018-1501-0.
(28) Patterson, B. H.; Combs, G. F., Jr.; Taylor, P. R.; Patterson, K. Y.; Moler, J. E.; Wastney, M. E. Selenium kinetics in humans change following 2 years of supplementation with selenomethionine. Front. Endocrinol. (Lausanne) 2021, 12, 621687. https://doi.org/10.3389/fendo.2021.621687.
(29) Marshall, J. R.; Burk, R. F.; Payne Ondracek, R.; Hill, K. E.; Perloff, M.; Davis, W.; Pili, R.; George, S.; Bergan, R. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget 2017, 8 (16), 26312-26322. https://doi.org/10.18632/oncotarget.15460.
(30) Jayachandran, P.; Knox, S. J.; Garcia-Cremades, M.; Savić, R. M. Clinical pharmacokinetics of oral sodium selenite and dosing implications in the treatment of patients with metastatic cancer. Drugs R D 2021, 21 (2), 169-178. https://doi.org/10.1007/s40268-021-00340-9.
(31) Di Dato, C.; Gianfrilli, D.; Greco, E.; Astolfi, M.; Canepari, S.; Lenzi, A.; Isidori, A. M.; Giannetta, E. Profiling of selenium absorption and accumulation in healthy subjects after prolonged L-selenomethionine supplementation. J. Endocrinol. Invest. 2017, 40 (11), 1183-1190. https://doi.org/10.1007/s40618-017-0663-5.
(32) Marshall, J. R.; Ip, C.; Romano, K.; Fetterly, G.; Fakih, M.; Jovanovic, B.; Perloff, M.; Crowell, J.; Davis, W.; French-Christy, R.; Dew, A.; Coomes, M.; Bergan, R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev. Res. (Phila). 2011, 4 (11), 1938-1944. https://doi.org/10.1158/1940-6207.CAPR-10-0259.
(33) Manzanares, W.; Biestro, A.; Galusso, F.; Torre, M. H.; Mañáy, N.; Facchin, G.; Hardy, G. High-dose selenium for critically ill patients with systemic inflammation: pharmacokinetics and pharmacodynamics of selenious acid: a pilot study. Nutrition 2010, 26 (6), 634-640. https://doi.org/10.1016/j.nut.2009.06.022.
(34) Brodin, O.; Eksborg, S.; Wallenberg, M.; Asker-Hagelberg, C.; Larsen, E. H.; Mohlkert, D.; Lenneby-Helleday, C.; Jacobsson, H.; Linder, S.; Misra, S.; Björnstedt, M. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: The SECAR study. Nutrients 2015, 7 (6), 4978-4994. https://doi.org/10.3390/nu7064978.
(35) Manzanares, W.; Hardy, G. Selenium supplementation in the critically ill: posology and pharmacokinetics. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12 (3), 273-280. https://doi.org/10.1097/MCO.0b013e32832a0cc2.
(36) Sherovski, P.; Ristovska, N.; Bogdanov, J.; Stafilov, T. Optimisation and validation of a method for determination of selenium in human plasma and blood by ETAAS and its clinical application. Bulg. Chem. Commun. 2022, 54 (4), 303-309. https://doi.org/10.34049/bcc.54.3.5473.
(37) Luty-Frackiewicz, A.; Jethon, Z.; Januszewska, L. Effect of smoking and alcohol consumption on the serum selenium level of Lower Silesian population. Sci. Total Environ. 2002, 285, 89-95. https://doi.org/10.1016/s0048-9697(01)00898-1.
(38) Arnaud, J.; Akbaraly, N. T.; Hininger, I.; Roussel, A. M.; Berr, C. Factors associated with longitudinal plasma selenium decline in the elderly: The EVA study. J. Nutr. Biochem. 2007, 18, 482-247. https://doi.org/10.1016/j.jnutbio.2006.09.004.
(39) Hawkes, W. C.; Alkan, F. Z.; Oehler, L. Absorption, distribution and excretion of selenium from beef and rice in healthy North American men. J. Nutr. 2003, 133, 3434-3442. https://doi.org/10.1093/jn/133.11.3434.
(40) Finley, J. W.; Duffield, A.; Ha, P.; Vanderpool, R. A.; Thomson, C. D. Selenium supplementation affects the retention of stable isotopes of selenium in human subjects consuming diets low in selenium. Br. J. Nutr. 1999, 82, 357-360. https://doi.org/10.1017/s0007114599001592.
(41) Bügel, S.; Larsen, E. H.; Sloth, J. J.; Flytlie, K.; Overvad, K.; Steenberg, L. C.; Moesgaard, S. Absorption, Excretion, and Retention of Selenium from a High Selenium Yeast in Men with a High Intake of Selenium. Food Nutr. Res. 2008, 52 (0), 1642. https://doi.org/10.3402/fnr.v52i0.1642.
(42) Levander, O. A.; Sutherland, B.; Morris, V. C.; King, J. Selenium Balance in Young Men during Selenium Depletion and Repletion. Am. J. Clin. Nutr. 1981, 34 (12), 2662–2669. https://doi.org/10.1093/ajcn/34.12.2662.
(43) Swanson, C. A.; Patterson, B. H.; Levander, O. A.; Veillon, C.; Taylor, P. R.; Helzlsouer, K.; McAdam, P. A.; Zech, L. A. Human [74Se]Selenomethionine Metabolism: A Kinetic Model. Am. J. Clin. Nutr. 1991, 54 (5), 917–926. https://doi.org/10.1093/ajcn/54.5.917.
(44) Patterson, B. H.; Zech, L. A.; Swanson, C. A.; Levander, O. A. Kinetic Modeling of Selenium in Humans Using Stable Isotope Tracers. J. Trace Elem. Electrolytes Health Dis. 1993, 17 (2), 117–120.
(45) Clark, L. C.; Combs, G. F., Jr.; Turnbull, B. W.; Slate, E. H.; Chalker, D. K.; Chow, J.; Davis, L. S.; Glover, R. A.; Graham, G. F.; Gross, E. G.; Krongrad, A.; Lesher, J. L., Jr.; Park, H. K.; Sanders, B. B., Jr.; Smith, C. L.; Taylor, J. R. Effects of Selenium Supplementation for Cancer Prevention in Patients with Carcinoma of the Skin. A Randomized Controlled Trial. JAMA 1996, 276 (24), 1957–1963.
(46) Heidari, Z.; Sheikhi, V. Serum Selenium Status in Graves' Disease and Hashimoto's Thyroiditis in an Iodine-Sufficient Area: A Case-Control Study. J. Res. Med. Sci. 2022, 23 (2), 27–87. https://doi.org/10.4103/jrms.jrms_57_21.
Downloads
Published
Versions
- 2025-06-29 (2)
- 2025-06-24 (1)
How to Cite
Issue
Section
License
Copyright (c) 2025 Pece Sherovski, Jane Bogdanov, Natasha Ristovska, Trajče Stafilov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
